FDA Publishes Complex Generics News Resource

August 5, 2022

Today the FDA is publishing a new web page to share the most recent FDA actions and activities related to complex generics. This new resource is part of FDA’s continued commitment to ensuring Americans have access to safe, effective, high-quality, and more affordable generic drugs.

Given FDA’s focus on regulatory and scientific initiatives to expand and strengthen this important area of our nation’s public health system, this page will be updated regularly with information about recent Agency actions related to complex generics, including:

  • notable approvals
  • guidance documents
  • research
  • events

Since these products are generally harder to develop, fewer exist, resulting in less market competition. This means that complex generics may be more expensive and less accessible to the patients who need them. Complex generics are a key component of FDA’s Drug Competition Action Plan, which aims to bring more drug competition to the market and address the high cost of medicines, and the Generic Drug User Fee Amendments, which include special provisions related to complex generics.

Complex Generics News Webpage

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




FDA North America

May 10, 2022

Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies

On May 5, 2022, the FDA announced the availability of a draft guidance for industry entitled Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies. This draft guidance...

Read the Full Article
FDA North America

May 9, 2022

FDA announces draft guidance on Benefit-Risk Considerations for Product Quality Assessments

Today, FDA announced the availability of a draft guidance for industry, Benefit-Risk Considerations for Product Quality Assessments. This guidance describes the benefit-risk principles applied by FDA...

Read the Full Article
FDA North America

April 29, 2022

Ulcerative Colitis: Developing Drugs for Treatment

Guidance Document April 2022. The purpose of this guidance is to help sponsors in the clinical development of drugs to treat adults with ulcerative colitis (UC). This guidance addresses the Food and...

Read the Full Article